Web3 de fev. de 2014 · Diffuse infiltrative invasion is a major cause for the dismal prognosis of glioblastoma multiforme (GBM), but the underlying mechanisms remain incompletely … WebThe heterodimer then induces transcription of many hypoxia response genes including EPO, VEGF, and GLUT1. HIF-alpha is regulated by von Hippel-Lindau (VHL) protein-mediated …
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic …
WebHIF/EPO pathway on FGF23 in humans without renal failure or anemia, we compared C-terminal and intact FGF23 levels and blood phosphate in normal control subjects to patients with EPO-producing tumors caused by gain-of-function mutations in HIF2A that resulted in activation of the HIF/EPO pathway, ele-vated EPO, and secondary polycythemia. Web27 de nov. de 2024 · The HIF2A mutation was confirmed to be the only pathogenic mutation, based on the American College of Medical Genetics and Genomics (ACMG) guidelines (Supplementary Table S3). Furthermore, protein levels of VHL, HIF1A, HIF2A, EPO, and VEGF estimated by immunohistochemical staining suggested hyperactivation … shaoxing li yuan import and export
HIF2a inhibitors for the treatment of VHL disease - PMC
Web6 de abr. de 2009 · Decrease in serum and liver iron and increase in serum EPO levels in intestine-specific Hif2a-knockout mice. ( A ) Quantification of serum and liver iron levels in vil- Cre + /HIF-1α fl/fl and vil- Cre + /HIF-2α fl/fl mice and WT littermates ( … Mutations in the EPAS1 gene are related to early-onset neuroendocrine tumors such as paragangliomas, somatostatinomas and/or pheochromocytomas. The mutations are commonly somatic missense mutations that locate in the primary hydroxylation site of HIF-2α, which disrupt the protein hydroxylation/degradation mechanism, and leads to protein stabilization and pseudohypoxic signaling. In addition, these neuroendocrine tumors release erythropoietin (EPO) … Web13 de abr. de 2015 · HIF2α inhibitors suppress aberrant expression of HIF target genes in the vhl mutant zebrafish. vhl–/– zebrafish display the human VHL disease signature phenotypes of erythrocytosis and inappropriate vessel proliferation (refs. 21, 22, and Figure 4A ). In humans, HIF2α is a critical target of VHL tumor suppressor protein, and … ponthibault